NASDAQ · ELDN

Eledon Pharmaceuticals, Inc.

$3.57 -$0.01 (-0.28%) 1D Pre-market

Key Metrics

$276.33M
Market cap
P/E · TTM
Revenue · TTM
−$78.15M
Net income
EPS · TTM $-1.01
Dividend yield
Free cash flow
Beta · 1Y 1.79
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Apr 16
    The stock moved +13.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 16
  • Mar 31
    The stock moved +13.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 31

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$276.33M
Enterprise value
Shares outstanding77.2M
52-wk range$1.35 – $4.60
Avg volume · 20D370.8K
Net cash
Book value / share$0.58
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Eledon Pharmaceuticals, Inc.
IPO dateSep 17, 2014
Employees33

Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC -145.8% · —

Financial Health

Current ratio8.44
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$100.12M

Cash Flow · TTM

Operating CF −$68.89M
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

0 / 9
Weak fundamentals · 0 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings